Rheumatology (Arthritis and Myositis)

Sang T. Kim; Savannah Bowman; Huifang Lu

doi:10.1007/978-3-031-00241-0_15

Rheumatology (Arthritis and Myositis)

Sang T. Kim, Savannah Bowman, Huifang Lu

General Internal Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Rheumatic immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI) therapy in patients with cancer can be grouped into articular, muscular, granulomatous, vasculitic, and other systemic irAEs. In a large registry study, the two most prevalent types of rheumatic irAEs were articular (36% of cases) and muscular (34%) [1]; these two types are the focus of this chapter. The articular cluster is comprised of arthralgias and arthritis, and the muscular cluster is comprised of myalgias, myositis, and polymyalgia rheumatica (PMR)-like syndrome. Complete resolution of arthritic and myositis symptoms is expected in most patients after the discontinuation of ICI and often a course of treatment with immunosuppression. However, persistent inflammatory arthritis that requires prolonged DMARDs (disease-modifying antirheumatic drugs) has been reported.

Original language	English (US)
Title of host publication	Managing Immunotherapy Related Organ Toxicities
Subtitle of host publication	A Practical Guide
Publisher	Springer International Publishing
Pages	301-313
Number of pages	13
ISBN (Electronic)	9783031002410
ISBN (Print)	9783031002403
DOIs	https://doi.org/10.1007/978-3-031-00241-0_15
State	Published - Jan 1 2022

Keywords

Giant cell arteritis
Inflammatory arthritis
Myositis
Polymyalgia rheumatica-like syndrome
Rhabdomyolysis

ASJC Scopus subject areas

General Medicine
General Immunology and Microbiology

Access to Document

10.1007/978-3-031-00241-0_15

Cite this

@inbook{26ef43cc05a24688ae433c7ad4f6a00e,

title = "Rheumatology (Arthritis and Myositis)",

abstract = "Rheumatic immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI) therapy in patients with cancer can be grouped into articular, muscular, granulomatous, vasculitic, and other systemic irAEs. In a large registry study, the two most prevalent types of rheumatic irAEs were articular (36% of cases) and muscular (34%) [1]; these two types are the focus of this chapter. The articular cluster is comprised of arthralgias and arthritis, and the muscular cluster is comprised of myalgias, myositis, and polymyalgia rheumatica (PMR)-like syndrome. Complete resolution of arthritic and myositis symptoms is expected in most patients after the discontinuation of ICI and often a course of treatment with immunosuppression. However, persistent inflammatory arthritis that requires prolonged DMARDs (disease-modifying antirheumatic drugs) has been reported.",

keywords = "Giant cell arteritis, Inflammatory arthritis, Myositis, Polymyalgia rheumatica-like syndrome, Rhabdomyolysis",

author = "Kim, {Sang T.} and Savannah Bowman and Huifang Lu",

note = "Publisher Copyright: {\textcopyright} The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022",

year = "2022",

month = jan,

day = "1",

doi = "10.1007/978-3-031-00241-0_15",

language = "English (US)",

isbn = "9783031002403",

pages = "301--313",

booktitle = "Managing Immunotherapy Related Organ Toxicities",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Rheumatology (Arthritis and Myositis)

AU - Kim, Sang T.

AU - Bowman, Savannah

AU - Lu, Huifang

N1 - Publisher Copyright: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Rheumatic immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI) therapy in patients with cancer can be grouped into articular, muscular, granulomatous, vasculitic, and other systemic irAEs. In a large registry study, the two most prevalent types of rheumatic irAEs were articular (36% of cases) and muscular (34%) [1]; these two types are the focus of this chapter. The articular cluster is comprised of arthralgias and arthritis, and the muscular cluster is comprised of myalgias, myositis, and polymyalgia rheumatica (PMR)-like syndrome. Complete resolution of arthritic and myositis symptoms is expected in most patients after the discontinuation of ICI and often a course of treatment with immunosuppression. However, persistent inflammatory arthritis that requires prolonged DMARDs (disease-modifying antirheumatic drugs) has been reported.

AB - Rheumatic immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI) therapy in patients with cancer can be grouped into articular, muscular, granulomatous, vasculitic, and other systemic irAEs. In a large registry study, the two most prevalent types of rheumatic irAEs were articular (36% of cases) and muscular (34%) [1]; these two types are the focus of this chapter. The articular cluster is comprised of arthralgias and arthritis, and the muscular cluster is comprised of myalgias, myositis, and polymyalgia rheumatica (PMR)-like syndrome. Complete resolution of arthritic and myositis symptoms is expected in most patients after the discontinuation of ICI and often a course of treatment with immunosuppression. However, persistent inflammatory arthritis that requires prolonged DMARDs (disease-modifying antirheumatic drugs) has been reported.

KW - Giant cell arteritis

KW - Inflammatory arthritis

KW - Myositis

KW - Polymyalgia rheumatica-like syndrome

KW - Rhabdomyolysis

UR - http://www.scopus.com/inward/record.url?scp=85163548326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85163548326&partnerID=8YFLogxK

U2 - 10.1007/978-3-031-00241-0_15

DO - 10.1007/978-3-031-00241-0_15

M3 - Chapter

AN - SCOPUS:85163548326

SN - 9783031002403

SP - 301

EP - 313

BT - Managing Immunotherapy Related Organ Toxicities

PB - Springer International Publishing

ER -

Rheumatology (Arthritis and Myositis)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this